<i>VEGF-A</i> and <i>ICAM-1</i> Gene Polymorphisms as Predictors of Clinical Outcome to First-Line Bevacizumab-Based Treatment in Metastatic Colorectal Cancer.

Int J Mol Sci · 2019 · PMC6888109 · PMID 31752122

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

reported similar results in patients treated with bevacizumab and FOLFIRI, with OS of 26.3 and 15.9 months in wild type and mutant tumors, respectively, although their results did not reach statistical significance [ 38 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.